Receptor activator of nuclear factor-kappa B ligand (RANKL) stimulates bone-associated tumors through functional RANK expressed on bone-associated cancer cells?
K. Mori1, K. Ando1, D. Heymann2,3,4 and F. Rédini2,3
1Department of Orthopaedic Surgery, Shiga University of Medical Science, Shiga, Japan, 2INSERM, ERI 7, Nantes, France, 3Université de Nantes, Nantes Atlantique Universités, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, France and 4Department of Histology, Hotel Dieu Hospital, Nantes, F-44035 France.
Offprint requests to: Dr. K. Mori, Department of Orthopaedic Surgery, Shiga University of Medical Science, Tsuknowa-cho, Seta, Otsu, Shiga, 520-2192, Japan. e-mail: kanchi@belle.shiga-med.ac.jp
Summary. Primary and secondary bone tumors clearly deteriorate quality of life and the activity of daily living of patients. These undesirable diseases become a major social and economic burden. As both primary and secondary bone tumors develop in the unique bone tissue, it is therefore necessary to understand bone cell biology in tumor bone environment. Recent findings of the Receptor Activator of Nuclear Factor-κB ligand (RANKL)/RANK/osteoprotegerin (OPG) molecular triad, the key regulators of bone remodeling, opened new era of bone research. Although RANK is an essential receptor for osteoclast formation, activation and survival, functional RANK expression has been recently identified on several bone-associated tumor cells. When RANK is expressed on secondary bone tumor cells, it is implicated in tumor cell migration, whereas this is not the case for primary bone tumors. In any case, RANK is not involved in RANK-positive cell proliferation or death. In two models of bone metastases secondary to melanoma or prostate carcinoma, in vivo neutralization of RANKL by OPG resulted in complete protection from paralysis, due to metastases of vertebral body, and a marked reduction in tumor burden in bones, but not in other organs. OPG also decreased tumor formation and tumor burden in a mouse model of primary bone tumor, osteosarcoma. In all these models, tumor cells express RANK. These data revealed that local differentiation factors, such as RANKL, play an important role in cell migration in a metastatic tissue-specific manner. These findings substantiate the novel direct role of RANKL/RANK in bone-associated tumors, and its capability of representing new therapeutic targets. Histol Histopathol 24, 235-242 (2009)
Key words: RANK, RANKL, Bone metastasis, Migration
DOI: 10.14670/HH-24.235